Search results
Results From The WOW.Com Content Network
Central serous chorioretinopathy (CSC or CSCR), also known as central serous retinopathy (CSR), is an eye disease that causes visual impairment, often temporary, usually in one eye. [ 1 ] [ 2 ] When the disorder is active it is characterized by leakage of fluid under the retina that has a propensity to accumulate under the central macula.
Verteporfin is also used off-label for the treatment of central serous retinopathy. [4] ... The 4 weeks of treatment resulted in mild extravascular hemolysis and ...
Central serous chorioretinopathy (pachychoroid stage II) with subretinal fluid (black triangle in the middle) and a markedly thickened, congested choroid (white arrowheads). Pachychoroid disorders of the macula represent a group of diseases affecting the central part of the retina of the eye , the macula .
Central or paracentral scotoma [2] [3] Vision loss due to solar retinopathy is typically reversible, [ 4 ] lasting for as short as one month [ 2 ] to over one year. [ 3 ] The fundus changes are variable and usually bilateral, mild cases often show no alteration and moderate to severe cases show a foveal yellow spot on the first days after exposure.
During treatment with pyrimethamine, leukocyte and platelet counts should be monitored weekly. Folinic acid protects against the decrease in platelets and white blood cells induced by pyrimethamine. Prednisone may be used for 3–6 weeks to reduce macular or optic nerve inflammation and can be started on day 3 of antibiotic therapy.
Central nervous system CNV Choroidal neovascularization: CRAO Central retinal artery occlusion CRVO Central retinal vein occlusion CSR Central serous retinopathy CVA Cerebrovascular accident Dx Diagnosis dDx Differential diagnosis DR Diabetic retinopathy: ERM Epiretinal membrane ESR Erythrocyte sedimentation rate FTMH Full thickness macular ...
Birdshot chorioretinopathy may show resistance to treatment. Immunosuppressant therapy along with oral corticosteroid has been somewhat effective in slowing down the progressive inflammation associated with the disorder, preserving visual integrity as much as possible. Long-term use of such medications must be closely monitored, however, due to ...
The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa (2004) Testing intravitreal toxicity of Bevacizumab (Avastin), (2006) Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study (2013).